Literature DB >> 30009533

Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma.

Meret Henry1,2, Steven Buck1, Süreyya Savaşan1,2.   

Abstract

BACKGROUND: The role of flow cytometry in diagnosis and management of Hodgkin lymphoma (HL) remains limited. As knowledge emerges of the tumor microenvironment in this disease, various methods are being evaluated in its study. This study examines the microenvironment using flow cytometry to assess differences between subtypes and clinicopathologic correlates. PROCEDURE: A retrospective cross-sectional study was performed analyzing the tumor immunophenotype, by flow cytometry, for 31 children with classical HL. Correlation was made with patient information, including outcome.
RESULTS: The makeup of the tumor microenvironment varies across subtype of HL, with T cells predominating in nodular sclerosis (NS), and similar proportions of B and T cells in mixed cellularity (MC). CD4 cells predominate in NS, whereas CD8 more so in MC subtype. The rate of continuous complete remission is significantly higher in the MC subgroup. Last, the proportion of HLA-DR/CD38 copositive lymphocytes was an independent prognostic factor for relapse/refractoriness.
CONCLUSIONS: This study indicates that flow cytometry can be used to examine the tumor microenvironment in HL and that percentage of HLA-DR/CD38 copositive lymphocytes may be a biomarker for relapse and refractoriness in pediatric HL.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Hodgkin lymphoma; biomarker; flow cytometry; immunophenotype; tumor microenvironment

Mesh:

Year:  2018        PMID: 30009533      PMCID: PMC6854677          DOI: 10.1002/pbc.27307

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  32 in total

1.  Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Authors:  Beatriz Sánchez-Espiridión; Ana M Martin-Moreno; Carlos Montalbán; L Jeffrey Medeiros; Francisco Vega; Anas Younes; Miguel A Piris; Juan F Garcia
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes.

Authors:  Adam C Seegmiller; Nitin J Karandikar; Steven H Kroft; Robert W McKenna; Yin Xu
Journal:  Cytometry B Clin Cytom       Date:  2009-05       Impact factor: 3.058

3.  Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases.

Authors:  M Engel; M F Essop; P Close; P Hartley; G Pallesen; C Sinclair-Smith
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

4.  Macrophages predict treatment outcome in Hodgkin's lymphoma.

Authors:  Christian Steidl; Pedro Farinha; Randy D Gascoyne
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

5.  The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>.

Authors:  Sara Alonso-Álvarez; Maria Belén Vidriales; Maria Dolores Caballero; Oscar Blanco; Noemí Puig; Alejandro Martin; Maria Jesús Peñarrubia; Esther Zato; Josefina Galende; Abelardo Bárez; Miguel Alcoceba; Alberto Orfão; Marcos González; Ramón García-Sanz
Journal:  Leuk Lymphoma       Date:  2016-10-12

6.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

7.  Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them.

Authors:  Kerry J Savage; Christian Steidl
Journal:  Expert Rev Hematol       Date:  2016-10-17       Impact factor: 2.929

8.  Prognostic factors and treatment outcome in childhood Hodgkin disease.

Authors:  Aynur Oguz; Ceyda Karadeniz; F Visal Okur; E Caglar Citak; F Guçlu Pinarli; Huseyin Bora; Nalan Akyurek
Journal:  Pediatr Blood Cancer       Date:  2005-10-15       Impact factor: 3.167

9.  Flow cytometry can diagnose classical hodgkin lymphoma in lymph nodes with high sensitivity and specificity.

Authors:  Jonathan R Fromm; Anju Thomas; Brent L Wood
Journal:  Am J Clin Pathol       Date:  2009-03       Impact factor: 2.493

10.  Hodgkin lymphoma in very young children: Clinical characteristics and outcome of treatment.

Authors:  Asim Belgaumi; Amani Al-Kofide; Nicey Joseph; Rubina Jamil-Malik; Yasser Khafaga; Rajeh Sabbah
Journal:  Leuk Lymphoma       Date:  2008-05
View more
  3 in total

Review 1.  The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good.

Authors:  Victoria Menéndez; José L Solórzano; Sara Fernández; Carlos Montalbán; Juan F García
Journal:  Cancers (Basel)       Date:  2022-03-07       Impact factor: 6.639

2.  High percentages of peripheral blood T-cell activation in childhood Hodgkin's lymphoma are associated with inferior outcome.

Authors:  Fengqing Cai; Hui Gao; Zhongsheng Yu; Kun Zhu; Weizhong Gu; Xiaoping Guo; Xiaojun Xu; Hongqiang Shen; Qiang Shu
Journal:  Front Med (Lausanne)       Date:  2022-08-10

3.  Flow cytometry assessment of reactive T-cells distinguishes classic Hodgkin lymphoma from benign lymphadenopathy in children.

Authors:  Hui Gao; Fengqing Cai; Lei Liu; Hongqiang Shen
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.